The tissue is the issue: personalized medicine for non-small cell lung cancer

The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, with particular reference to the detection of EML4-ALK gene rearrangements. Different molecular assays...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 16; no. 20; pp. 4909 - 4911
Main Authors Hirsch, Fred R, Wynes, Murry W, Gandara, David R, Bunn, Jr, Paul A
Format Journal Article
LanguageEnglish
Published United States 15.10.2010
Subjects
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - metabolism
Humans
Immunohistochemistry
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - metabolism
Molecular Targeted Therapy - methods
Precision Medicine - methods
Online AccessGet full text

Cover

Abstract The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, with particular reference to the detection of EML4-ALK gene rearrangements. Different molecular assays, validation, and clinical application to different types of tissue specimens are discussed.
AbstractList The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, with particular reference to the detection of EML4-ALK gene rearrangements. Different molecular assays, validation, and clinical application to different types of tissue specimens are discussed. Clin Cancer Res; 16(20); 4909–11. ©2010 AACR.
The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, with particular reference to the detection of EML4-ALK gene rearrangements. Different molecular assays, validation, and clinical application to different types of tissue specimens are discussed.
Author Wynes, Murry W
Hirsch, Fred R
Gandara, David R
Bunn, Jr, Paul A
Author_xml – sequence: 1
  givenname: Fred R
  surname: Hirsch
  fullname: Hirsch, Fred R
  email: Fred.Hirsch@ucdenver.edu
  organization: University of Colorado Cancer Center, Aurora, Colorado 80045, USA. Fred.Hirsch@ucdenver.edu
– sequence: 2
  givenname: Murry W
  surname: Wynes
  fullname: Wynes, Murry W
– sequence: 3
  givenname: David R
  surname: Gandara
  fullname: Gandara, David R
– sequence: 4
  givenname: Paul A
  surname: Bunn, Jr
  fullname: Bunn, Jr, Paul A
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20926402$$D View this record in MEDLINE/PubMed
BookMark eNo9kMlOwzAQhi1URBd4BJBvnFxmnDhxuKGITSpCQuVsOY5Dg7IUOznA0-Oohcts-mf7lmTW9Z0l5BJhjSjkDUIqGcQRXxvjGALjAOKELFCIlEU8EbMQ_2nmZOn9JwDGCPEZmXPIeBIDX5CX7c7SofZ-tLT2dNhNLiS3dG-d7zvd1D-2pK0ta1N3lla9o-ES5lvdNNTYYJqx-6BGd8a6c3Ja6cbbi6NfkfeH-23-xDavj8_53YaZmOPAMEUDWVSkBWY6TWSRYVHKApK4xFhUVWo5piWUpQGBPAuxCR9xnRiLBUoTrcj1Ye7e9V-j9YNqaz8dozvbj16lQsoo4YkMSnFQGtd772yl9q5utftWCGoCqSZIaoKk8vxtqk4gQ9_VccNYhOf_u_7IRb-xynAE
CitedBy_id crossref_primary_10_56050_01205498_2316
crossref_primary_10_1093_annonc_mds137
crossref_primary_10_5858_arpa_2012_0659_ED
crossref_primary_10_1186_s40169_017_0135_8
crossref_primary_10_2169_naika_103_1281
crossref_primary_10_1016_j_apsb_2018_04_005
crossref_primary_10_1002_cncy_20199
crossref_primary_10_1016_j_chest_2018_08_1035
crossref_primary_10_1097_JTO_0b013e31820bfcba
crossref_primary_10_5858_arpa_2012_0508_RA
crossref_primary_10_5858_arpa_2012_0246_RA
crossref_primary_10_1016_j_lungcan_2019_06_002
crossref_primary_10_1016_j_semcancer_2016_08_007
crossref_primary_10_5858_arpa_2012_0176_OA
crossref_primary_10_3390_tomography8060236
crossref_primary_10_1177_1758834011419002
crossref_primary_10_1016_j_jasc_2015_06_005
crossref_primary_10_1097_PAT_0000000000000324
crossref_primary_10_18632_oncotarget_24505
crossref_primary_10_1002_dc_22905
crossref_primary_10_1016_j_mjafi_2017_09_005
crossref_primary_10_1634_theoncologist_2015_0114
crossref_primary_10_1080_01913123_2019_1692118
crossref_primary_10_1097_LBR_0b013e318229656e
crossref_primary_10_3390_cancers12061627
crossref_primary_10_1016_j_lungcan_2013_08_025
crossref_primary_10_1038_labinvest_2013_92
crossref_primary_10_1016_j_critrevonc_2021_103525
crossref_primary_10_1586_era_11_157
crossref_primary_10_1007_s11523_014_0332_y
crossref_primary_10_1111_1759_7714_12072
crossref_primary_10_1373_clinchem_2012_185132
crossref_primary_10_1097_JTO_0b013e31823815d3
crossref_primary_10_1371_journal_pone_0116388
crossref_primary_10_1177_1010428317691186
crossref_primary_10_1016_j_critrevonc_2024_104332
crossref_primary_10_1002_cncr_27444
crossref_primary_10_1016_j_biocel_2013_07_013
crossref_primary_10_2217_pme_13_19
crossref_primary_10_1016_j_cllc_2016_12_002
crossref_primary_10_1097_LBR_0b013e31823302b7
crossref_primary_10_1007_s12094_012_0983_z
crossref_primary_10_1007_s00428_016_1906_0
crossref_primary_10_1111_cyt_13302
crossref_primary_10_1038_modpathol_2013_122
crossref_primary_10_1080_17476348_2017_1235975
crossref_primary_10_1371_journal_pone_0150197
crossref_primary_10_1007_s00408_013_9458_4
crossref_primary_10_1097_JTO_0000000000000024
crossref_primary_10_1016_j_lungcan_2019_05_017
crossref_primary_10_1016_j_critrevonc_2018_03_004
crossref_primary_10_1007_s10585_015_9733_2
crossref_primary_10_1002_cncr_31055
crossref_primary_10_1164_ajrccm_187_4_450a
crossref_primary_10_1016_j_lungcan_2022_08_004
crossref_primary_10_4103_1742_6413_129187
Cites_doi 10.1158/1078-0432.CCR-09-2167
10.1002/emmm.201000070
10.1056/NEJMoa0810699
10.1016/S1470-2045(09)70364-X
10.1158/1078-0432.CCR-09-2845
10.1056/NEJMoa0909530
10.1038/ng1975
10.1158/1078-0432.CCR-10-0099
ContentType Journal Article
Copyright 2010 AACR.
Copyright_xml – notice: 2010 AACR.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1158/1078-0432.ccr-10-2005
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1557-3265
EndPage 4911
ExternalDocumentID 10_1158_1078_0432_CCR_10_2005
20926402
Genre Journal Article
GroupedDBID ---
18M
29B
2FS
2WC
34G
39C
3O-
476
4H-
53G
5GY
5RE
5VS
6J9
ABOCM
ACGFO
ACIWK
ACPRK
ACSVP
ADBBV
ADCOW
AENEX
AFFNX
AFHIN
AFOSN
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BR6
BTFSW
C1A
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
FRP
GX1
H13
IH2
KQ8
L7B
LSO
NPM
OK1
P0W
P2P
QTD
RCR
RHF
RHI
RNS
SJN
TR2
UDS
W2D
W8F
WOQ
YKV
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c421t-171c093b7b19a768b91bd8b064d145ff7e217d0ddc0512917dc3262a6ce1b18c3
ISSN 1078-0432
IngestDate Fri Oct 25 03:26:52 EDT 2024
Thu Nov 21 21:03:04 EST 2024
Sat Sep 28 07:57:41 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 20
Language English
License 2010 AACR.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c421t-171c093b7b19a768b91bd8b064d145ff7e217d0ddc0512917dc3262a6ce1b18c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://aacrjournals.org/clincancerres/article-pdf/16/20/4909/1991801/4909.pdf
PMID 20926402
PQID 758836268
PQPubID 23479
PageCount 3
ParticipantIDs proquest_miscellaneous_758836268
crossref_primary_10_1158_1078_0432_CCR_10_2005
pubmed_primary_20926402
PublicationCentury 2000
PublicationDate 2010-10-15
PublicationDateYYYYMMDD 2010-10-15
PublicationDate_xml – month: 10
  year: 2010
  text: 2010-10-15
  day: 15
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical cancer research
PublicationTitleAlternate Clin Cancer Res
PublicationYear 2010
References Danenberg (2022061022552046900_bib9) 2010; 28 [15S]
Thomas (2022061022552046900_bib6) 2007; 39
Sakairi (2022061022552046900_bib1) 2010; 16
Kim (2022061022552046900_bib12) 2010
Dancey (2022061022552046900_bib13) 2010; 16
Dias-Santagata (2022061022552046900_bib7) 2010; 2
Maemondo (2022061022552046900_bib4) 2010; 362
Mino-Kenudson (2022061022552046900_bib10) 2010; 16
Salido (2022061022552046900_bib11)
Mok (2022061022552046900_bib2) 2009; 361
Bang (2022061022552046900_bib5) 2010; 28 [18S]
Su (2022061022552046900_bib8)
Mitsudomi (2022061022552046900_bib3) 2010; 11
References_xml – volume: 16
  start-page: 1745
  year: 2010
  ident: 2022061022552046900_bib13
  article-title: Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-2167
  contributor:
    fullname: Dancey
– volume: 2
  start-page: 146
  year: 2010
  ident: 2022061022552046900_bib7
  article-title: Rapid targeted mutational analysis of human tumors: a clinical platform to guide personalized medicine
  publication-title: EMBO Mol Med
  doi: 10.1002/emmm.201000070
  contributor:
    fullname: Dias-Santagata
– volume: 361
  start-page: 947
  year: 2009
  ident: 2022061022552046900_bib2
  article-title: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0810699
  contributor:
    fullname: Mok
– volume: 11
  start-page: 121
  year: 2010
  ident: 2022061022552046900_bib3
  article-title: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomized phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(09)70364-X
  contributor:
    fullname: Mitsudomi
– volume: 16
  start-page: 1561
  year: 2010
  ident: 2022061022552046900_bib10
  article-title: A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-2845
  contributor:
    fullname: Mino-Kenudson
– volume: 362
  start-page: 2380
  year: 2010
  ident: 2022061022552046900_bib4
  article-title: Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0909530
  contributor:
    fullname: Maemondo
– ident: 2022061022552046900_bib8
  article-title: A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small cell lung cancer
  publication-title: J Mol Diagn
  contributor:
    fullname: Su
– start-page: Abstract nr LB-1
  year: 2010
  ident: 2022061022552046900_bib12
  article-title: The BATTLE (Biomarker Integrated Approaches of Targeted Therapy for Lung Cancer Elimination): Personalizing therapy for lung cancer
  contributor:
    fullname: Kim
– volume: 39
  start-page: 347
  year: 2007
  ident: 2022061022552046900_bib6
  article-title: High-throughput oncogene mutation profiling in human cancer
  publication-title: Nat Genet
  doi: 10.1038/ng1975
  contributor:
    fullname: Thomas
– volume: 28 [15S]
  start-page: 731s
  year: 2010
  ident: 2022061022552046900_bib9
  article-title: A novel RT-PCR approach to detecting EML4-ALK fusion genes in archival NSCLC tissue
  publication-title: J Clin Oncol
  contributor:
    fullname: Danenberg
– ident: 2022061022552046900_bib11
  article-title: ALK amplification is frequent in non-small cell lung cancer and it is associated with EGFR FISH positivity in adenocarcinoma
  publication-title: J Thorac Oncol
  contributor:
    fullname: Salido
– volume: 28 [18S]
  start-page: 946s
  year: 2010
  ident: 2022061022552046900_bib5
  article-title: Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer
  publication-title: J Clin Oncol
  contributor:
    fullname: Bang
– volume: 16
  start-page: 4938
  year: 2010
  ident: 2022061022552046900_bib1
  article-title: EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-10-0099
  contributor:
    fullname: Sakairi
SSID ssj0014104
Score 2.324963
Snippet The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of...
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
StartPage 4909
SubjectTerms Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - metabolism
Humans
Immunohistochemistry
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - metabolism
Molecular Targeted Therapy - methods
Precision Medicine - methods
Title The tissue is the issue: personalized medicine for non-small cell lung cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/20926402
https://search.proquest.com/docview/758836268
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgkRAXxJvykg_cqhQ7sROHGypbCmwXCbWiN8vOQ1ppWVZtetj99czYjpsVi3hcosRVbWXmk_PNeB6EvEaKjFVkEm5ykQgjssQ2UiamyFRrgc3xArORF8f5fCU-reV637PVZZd0dlJdXptX8j9ahTHQK2bJ_oNm46QwAPegX7iChuH61zrunOSwLzlSSPeAVv55T7IvgVH2B-guphDs_WT7HU-k0Wk_Pt1h1i3qfjMkqtM-Y9L_NA5FgaLzeH6y2fouUjOMYI_nRd8uQu1_0ODmYhw9OB-cx8LEMPpBoGKg0BijGDyrwQuBER0s8XmYYeNkWKlXZFd31nyAoJQN9klRsnLwzRWl33F_3c-lcq6FMPlkOv2KK6MrbP8B6w_tj7_o2eroSC8P18ub5BaWRsRuCu8_fo7nSoK7hpJxwpDTBcu8uXaRq2zlNyaIoyLLe-RusCHoOw-I--RGc_aA3F4EJT8kC8AF9bigJ1sKuKDu4S0dooL2qKCAChpRQREVFFFBveofkdXscDmdJ6FtRlKJlHcJL3jFyswWlpcGrElbclsrC9yz5kK2bdGAGVqzuq4Ysj24r4DDpyavGm65qrLH5AAWbZ4SqnhblgXnRhgmuBKqNaxVUjaszisu2xGZ9OLR5746inZWpVQa5alRnhrkiaMozxGhvRA17GP4Ruas-bHbarBbFZZGUiPyxAs3zpiyEmg7S5_9-c_PyZ09Ol-Qg26za14Ca-zsKweEnz1hZyQ
link.rule.ids 314,780,784,27924,27925
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+tissue+is+the+issue%3A+personalized+medicine+for+non-small+cell+lung+cancer&rft.jtitle=Clinical+cancer+research&rft.au=Hirsch%2C+Fred+R&rft.au=Wynes%2C+Murry+W&rft.au=Gandara%2C+David+R&rft.au=Bunn%2C+Paul+A&rft.date=2010-10-15&rft.issn=1078-0432&rft.volume=16&rft.issue=20&rft.spage=4909&rft.epage=4911&rft_id=info:doi/10.1158%2F1078-0432.CCR-10-2005&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon